IMMUNO-BIOLOGICAL LABORATORIES COIMMUNO-BIOLOGICAL LABORATORIES COIMMUNO-BIOLOGICAL LABORATORIES CO

IMMUNO-BIOLOGICAL LABORATORIES CO

No trades
See on Supercharts

4570 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. It operates through the following segments: Diagnostics and Reagents, Genetically Modified Silkworm, Testing, and Cosmetics-related. The Diagnostics and Reagents segment deals with the research and development of reagents and pharmaceutical products as well as in vitro diagnostic pharmaceuticals. The Genetically Modified Silkworm segment sells products using the cocoon of genetically modified silkworm. The Testing segment offers prevention and diagnostic support on top of drug discovery and research support in lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics-related segment develops and manufactures cosmetic products containing Neosilk-Human Collagen I. The company was founded on September 9, 1982 and is headquartered in Fujioka, Japan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

4570 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company